https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45277 0.14). Conclusion: In this secondary analysis of a primary efficacy study, PD was a common comorbidity among those with MDD, but was not a significant predictor of functional outcomes. This study adds to the limited literature on PD in randomized controlled trials for MDD.]]> Wed 26 Oct 2022 17:13:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39815 I² statistic. This systematic review was registered with PROSPERO (CRD42018089279) and the protocol is published. Results: The search yielded 11,640 studies. Subsequent to removing duplicates, 9657 studies were screened at title and abstract stage and 1456 were assessed at full-text stage. Eighteen studies met criteria for inclusion in this review. Meta-analysis did not reveal a significant difference between groups for treatment outcome (standardised mean difference 0.22 [-0.09, 0.54]; I²: 69%, p=0.17) and remission (risk ratio 0.84 [0.64, 1.11]; I²: 51%, p=0.22). Limitations: This review was limited by lack of studies on bipolar disorder. Conclusion: PD comorbidity does not appear to affect treatment efficacy of pharmacological interventions for adults with mood disorders.]]> Wed 10 Aug 2022 13:16:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:378 Tue 08 Jan 2019 15:22:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7346 Sat 24 Mar 2018 08:40:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7111 Sat 24 Mar 2018 08:34:09 AEDT ]]>